Method for the detection of an albumin isoform
The present invention provides methods for detecting, analyzing, and identifying biomolecules used to identifying patient with dengue-like symptom who are at risk of DHF. The inventive method comprises detecting in a sample from a subject dengue infected patient one or more biomarkers selected from the group consisting of IL-10, fibrinogen, C4A, immunoglobulin, tropomyosin, and three isoforms of albumin, and which are used in a predictive MARS model to detect patients with risk of developing DHF.
1. A sample fractionation method for albumin biomarker identification comprising:
(a) fractionating a sample derived from blood by size exclusion chromatography, wherein the sample has protein/peptide complexes dissociated by denaturation and the sample is spiked with a labeled protein of about 200 amino acid residues for differentiating protein and peptide pools;
(b) collecting a (i) protein pool comprising the fractions preceding the end of the labeled protein peak, and (ii) a peptide pool comprising the fractions after the end of the labeled protein peak and before the free dye peak;
(c) incubating the collected protein pool to allow for renaturation of the collected proteins in the protein pool;
(d) depleting the protein pool by exposing the protein pool to an antibody depletion column and collecting column flow through to produce a depleted sample;
(e) labeling the depleted sample with an uncharged thiol reactive label forming a saturated fluorescence labeled sample;
(f) conducting two dimensional (2D) gel electrophoresis on the saturated fluorescence labeled sample, producing a 2D gel;
(g) imaging the 2D gel and identifying a protein(s) of interest, wherein the protein of interest is an albumin isoform; and
(h) conducting mass spectrometry analysis of the protein(s) of interest.
2. The method of claim 1 , wherein the size exclusion chromatography uses a size exclusion column having a separation range between molecular weights of 3,000 to 70,000 daltons.
3. The method of claim 1 , wherein the spiked labeled protein is a labeled thaumatin.
4. The method of claim 1 , wherein the antibody depletion column is an IgY antibody depletion column.
5. The method of claim 1 , wherein the thiol reactive label is bodipy FL-maleimide.